 SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., April 12, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell AlloCAR TTM therapies for cancer, and SpringWorks Therapeutics, Inc. Nasdaq: SWTX, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating ALLO-715, Allogenes investigational anti-B-cell maturation antigen BCMA AlloCAR T therapy, in combination with nirogacestat, SpringWorks investigational gamma secretase inhibitor GSI, in patients with relapsed or refractory multiple myeloma. 